News

FDA recently approved the New Drug Application (NDA) for (lorcaserin HCl) CIV extended-release 20 mg tablets (Belviq XR, Eisai Inc. and Arena Pharmaceuticals), a once-a day dosing option for chronic weight management.

FDA recently approved an expansion to the prescribing information for darunavir (Prezista, Janssen Therapeutics), to treat pregnant women with HIV.

A new “secret shopper” study shows that problems exist for patients with acute conditions accessing services for patients. Effectively addressing issues of network adequacy may require more accurate provider information.

The Managed Healthcare Executive editorial advisory board says healthcare executives should watch out for these seven leadership deficiencies.

Medication nonadherence and complications from type 2 diabetes is resulting in signficant economic and societal burdens in the U.S. and other countries, according to a new report.

President Obama recently reviewed the ACA. Find out what he said are the top successes, and how policy insiders are reacting.

Clinton and Trump are keeping mum about some healthcare issues, and that’s raising some critical questions. Managed Healthcare Executive asked industry experts to comment on what topics presidential candidates are being quiet about, and why they suspect they’re not talking about them.

A new survey from Willis Towers Watson has interesting findings related to how employers view exchange viability

Shifting patient demographics will create an ideal scenario for the online/mail-order pharmacy market in the next five to ten years.

The impacts of the ever-changing health care marketplace and how employers, brokers and carriers have adapted

Over the next decade, health spending is expected to grow at an average rate of 5.8% per year.

FDA approved evolocumab (Repatha, Amgen) Pushtronex system, the first monthly single-dose injection of a PCSK9 inhibitor. Repatha was already approved by FDA as the only PCSK9 inhibitor with a monthly dose last August.

A new study suggests that patients are willing to use antibiotics without contacting a doctor. Here’s how execs can curb this and avoid antibiotic resistance.

Find out what drives patients to international destinations for treatments and what these destinations provide.

As payers look for growth opportunities internationally, they should watch nother growing trend: medical tourism.

Despite different drivers among healthcare leaders, telehealth is gaining momentum. Still, key barriers need to be addressed.

Expanding access to buprenorphine, a medication to treat opioid use disorder, is one of several new actions announced by Health and Human Services (HHS) to combat the opioid epidemic. Here are the top 4 new provisions from HHS.

From new outreach programs to multidisciplinary teams, here are some new strategies health plans are employing to fight the opioid epidemic

HHS is taking formal steps to address opioid addiction, a widely recognized national public health crisis. Find out the policy changes.

A new KFF issue brief finds that healthcare coverage problematic for some, even as coverage is gained through the ACA.

For the first time, FDA approved dronabinol oral solution (Syndros, Insys Therapeutics), a liquid formulation of the pharmaceutical cannabinoid dronabinol, a pharmaceutical version of tetrahydrocannabinol ("THC").

Karen B. DeSalvo, National Coordinator for Health Information Technology, gives the best courses of action for top technology challenges and opportunities facing healthcare executives.

A new Quest Diagnostics and Inovalon study cites barriers to value-based care, but offers advice on how to overcome them.

As asthma prevalence continues to rise in the adult and pediatric populations, U.S. healthcare spending on medications, especially branded inhalers, is expected to increase.

Express Scripts Exchange Pulse report found that utilization, particularly for traditional meds, was one of the biggest factors driving spending in 2015, accounting for more than half of the exchange plans $99 PMPY increase in spending between 2014 and 2015.

CMS finalized new rules that aim to enrich the Qualified Entity Program by expanding access to analyses and data that will help providers, employers, and others make more informed decisions about care delivery and quality improvement.

All antibiotic use has the potential to contribute to the development of antibiotic resistance. That’s why it is key to reduce inappropriate antibiotic use in order to slow the growth of resistance.

Health plans must find new and meaningful ways to connect with patients of diverse backgrounds.

Remote monitoring studies are missing the mark when assessing the value of the technology. Here’s why.

Is digital health integration the missing link in understanding chronic diseases and what should physicians be asking to ensure the data they want to receive is captured effectively?